EGFR and squamous cell lung carcinoma: Reflex testing decisions for histological subtype may also be influenced by current approved indications of available therapeutic options, as the use of osimertinib is restricted to adjuvant therapy following complete tumour resection in adult patients with stage IB-IIIA (TNM staging system for lung cancer seventh edition as per the ADAURA clinical trial) non-squamous cell lung carcinoma, harbouring EGFR exon 19 deletions or exon 21 (L858R) substitution mutations.7